Of the 63 MS patients, there were 15 patients untreated at enrolment time, 24 patients treated with interferon beta (15 Rebif®, 8 Avonex®, and 1 Betaferon®), 10 treated with fingolimod (Gilenya®), and 14 treated with other medications (natalizumab (Tysabri®), with no significant differences in EDSS values. Here, IFNB1 is linked to myeloid sarcoma.